Serotonin 5-HT3 Receptor Antagonists

01/01/2004 - "In conclusion, the study showed that almost all patients received prophylaxis for acute emesis and that there is overprescription of 5-HT3 antagonists. "
01/01/2006 - "All patients received at least one 5-HT3 antagonist for emesis prophylaxis. "
07/01/2002 - "Clinically, 5-HT3 antagonists are important in the treatment of emesis and have been used for the treatment of symptoms in functional bowel disease. "
04/01/2000 - "The effect of 5-HT3 antagonists was judged by both the score for the severity of the emesis and the frequency of vomiting. "
06/20/1993 - "5-HT3 antagonists represent a new class of drugs effective in the control of chemo- and radiotherapy-induced emesis. "

12/01/1989 - "5-HT3 antagonists at high doses are effective in treating nausea and at low doses in treating anxiety. "
11/01/2023 - "MEDLINE, EMBASE, PubMed, CENTRAL and CINAHL were searched from inception to 17 July 2023 for randomised controlled trials (RCTs) comparing inhaled IPA and a 5-HT3 antagonist for treatment of nausea. "
01/01/2021 - "5-HT3 antagonists: We found intraoperative nausea may be reduced by 5-HT3 antagonists (average risk ratio (aRR) 0.55, 95% confidence interval (CI) 0.42 to 0.71, 12 studies, 1419 women, low-certainty evidence). "
11/01/2023 - "IPA may provide rapid, effective relief of nausea when compared with 5-HT3 antagonists."
11/01/2023 - "We aimed to compare IPA with 5-HT3 antagonists for the treatment of nausea across all clinical settings. "

09/01/2020 - "Progress in pharmacological PONV prophylaxis includes a new generation of 5-HT3 antagonists. "
12/01/2016 - "Comparative Pharmacology and Guide to the Use of the Serotonin 5-HT3 Receptor Antagonists for Postoperative Nausea and Vomiting."
01/01/2006 - "This article explains the clinical pharmacology of 5-HT3 antagonists and provides recommendations for nursing management of PONV."
01/01/2005 - "Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same?"
01/01/1992 - "5-HT3 antagonists in postoperative nausea and vomiting."

08/01/1994 - "Ondansetron was very well tolerated; hence, further long-term studies with 5-HT3 antagonists alone or in combination with other treatment components may offer promise for treatment of alcoholism."
10/01/2005 - "Recently, we reported that ondansetron (a 5-HT3 antagonist) as an adjunct to cognitive behavioral therapy (CBT) produced significant within-group decreases (improvement) in drinking in adolescents with alcohol dependence. "
09/01/1994 - "Overall, these results do not support the hypothesis that the serotonin 5-HT3 antagonists would have robust therapeutic efficacy in the treatment of alcoholism."
01/01/2000 - "By attenuating the rewarding effects of ethanol or of ethanol conditioned cues (e.g., the operant environment), 5-HT3 antagonists may be useful in the treatment of alcohol abuse. "
03/01/2014 - "Finally, first clinical evidence suggests that the 5-HT3 antagonist ondansetron might possibly be used in future within a pharmacogenetic treatment approach in alcohol dependence."

04/01/2014 - "Despite the advent of 5-HT3 antagonists, control of delayed gastrointestinal adverse events with cancer chemotherapy is still not optimal. "
04/01/2000 - "[Effects of oral 5-HT3 antagonists on chemotherapy-induced emesis in patients with gynecologic cancers]."
01/01/2001 - "The study allowed an effective 5-HT3 antagonist protocol to be developed for use in the management of nausea and vomiting in cancer patients."
09/01/2012 - "Interaction between serotonin reuptake inhibitors, 5-HT3 antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: a case-control study."
02/01/1999 - "In relation to concerns about the use of corticosteroids in non-haematological cancer chemotherapy, we suggest that 8 mg or its equivalent should be used in combination with 5-HT3 antagonists until further research proves otherwise."